Ivo J. Huijbers

The Netherlands Cancer Institute — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index2.3kcitations87works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(17), DNA Repair Mechanisms(14), Ion channel regulation and function(14), Immunotherapy and Immune Responses(13), Cardiac electrophysiology and arrhythmias(12)

Publications87 total

Colorectal carcinoma progression is not influenced by the pseudokinase PEAK1
Scientific Reports·2024Open Access
Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice
Acta Pharmacologica Sinica·2024· 5 citedOpen Access
Table TS2 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS6 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS3 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS4 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS2 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Table TS1 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS5 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Table TS1 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Data from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Table TS2 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Data from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS4 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS3 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS2 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS1 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS6 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS5 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
Figure FS1 from Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Colin E.J. Pritchard(27), Ji‐Ying Song(12), Jos Jonkers(11), Anton Berns(8), Rahmen Bin Ali(8), Lona J. Kroese(8), Anne Paulien Drenth(6), Marieke van de Ven(6), Heinz Jacobs(6), Clare M. Isacke(5), Linda Henneman(5), Renske de Korte‐Grimmerink(5), Paul Krimpenfort(5), Martine H. van Miltenburg(4), Ewa M. Michalak(4), Maarten van Lohuizen(4), Eline van der Burg(4), Michael Sloth Trabjerg(4), John D. Nieland(4), Miranda Cozijnsen(3)